Dr. Varty received his GlaxoWellcome-sponsored Ph.D. in Neuropharmacology from the University of Hertfordshire, and post-doctoral training in Psychopharmacology from the University of California, San Diego. He is the EVP for Research Operations at PsychoGenics Inc., a profitable preclinical CNS service company engaged in psychiatric drug discovery. He has more than 20 years of experience in drug discovery (Schering-Plough, Sanofi, Merck), managing in vivo pharmacology groups and leading efforts to outsource in vivo research with commercial partners. Dr. Varty’s career has focused on drug discovery programs for treating schizophrenia, depression, anxiety, cognitive disorders, pain, neurodegenerative diseases, complications of diabetes, and fibrosis. He’s led several preclinical research programs that have progressed compounds into early and late stage clinical trials, including the successful approval of the neurokinin NK1 receptor antagonist, Varubi (rolapitant), for the treatment of chemotherapy-induced nausea and vomiting. Dr. Varty has published over 50 peer-reviewed scientific publications.